Should we continue to use renin–angiotensin–aldosterone system blockers in patients with COVID-19?

Patients with chronic kidney disease, chronic heart failure and hypertension have an increased risk of coronavirus disease 2019 (COVID-19)-related death. Renin–angiotensin–aldosterone system (RAS) blockers are commonly prescribed to decrease morbidity and mortality in these conditions. Following the...

Descripción completa

Detalles Bibliográficos
Autores principales: Copur, Sidar, Kanbay, Asiye, Kanbay, Mehmet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Editorial Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8755383/
https://www.ncbi.nlm.nih.gov/pubmed/35498886
http://dx.doi.org/10.1093/ckj/sfac001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8755383/
https://www.ncbi.nlm.nih.gov/pubmed/35498886
http://dx.doi.org/10.1093/ckj/sfac001

Ejemplares similares